Synonyms: example 158 [WO2018119036] | JNJ67856633
Compound class:
Synthetic organic
Comment: JNJ-67856633 is a selective, allosteric mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) protease inhibitor [1]. It was developed for antineoplastic potential.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
JNJ-67856633 has progressed to early clinical trial for CLL and non-Hodgkin lymphoma, either as monotherapy or in combination with a Janssen's BTK inhibitor JNJ-64264681. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03900598 | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Phase 1 Interventional | Janssen Research & Development, LLC | ||
NCT04657224 | A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Phase 1 Interventional | Janssen Research & Development, LLC |